We use iPSC lines from patients with Tuberous Sclerosis Complex disease to model the renal manifestations of the disease. The goal is to identify novel mechanisms of tumor and cyst formation driven by constitutive mTOR activation for the identification of novel therapeutic targets.
Lemos Lab 